X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Solifenacin Succinate is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used in combination to treat benign prostatic hyperplasia.
Lead Product(s): Solifenacin Succinate,Tamsulosin
Therapeutic Area: Urology Product Name: Vesomni-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Adamed Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
Under the agreement, Sandoz will get the rights to commercialize six products in the US across key therapeutic areas, including antifungal/antibiotic, oncology and pulmonary.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 04, 2023
Details:
Under the terms of collaboration, Zentiva will complement their product offering with the support of longstanding partners Adalvo with new molecules in a variety of therapeutical areas like Respiratory, CNS and Dermatology.
Lead Product(s): Undisclosed
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Zentiva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration January 09, 2023
Details:
Adalvo will be the sole and exclusive owner of the Onsolis® (fentanyl) and will obtain full rights on the product, taking over all existing business and all market authorizations, globally, including the US.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Onsolis
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 02, 2022
Details:
Icatibant, a complex injectable peptide product, forming part of high-value product, is an equivalent and more affordable version of Firazyr (Takeda/Shire), used used to treat a serious orphan disease, acute attacks of hereditary angioedema.
Lead Product(s): Icatibant Acetate
Therapeutic Area: Genetic Disease Product Name: Icatibant Acetate-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: AmbioPharm
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
The partnership includes a basket of difficult-to-make peptide products that will be used to treat various diseases, ranging from diabetes to immunology disorders, cardiologic and endocrinology diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Peptide
Partner/Sponsor/Collaborator: AmbioPharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
